Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study. (31st March 2019) - Plesner, Torben